Capital Markets Day: Commercial Execution and Innovation in Obesity Care

11 Commercial execution and innovation Obesity care WegovyⓇ has the potential to unlock the obesity market Branded AOM TRX in the US 2021 US Obesity care sales TRX count (000s) DKK billion 48 5.6 40 4.8 +21.1% 32 4.0 3.3 3.2 24 24 3.2 16 лучш 2.4 1.6 8 0.8 0 Jan 2019 0.0 Jan 2020 Jan Feb 2019 2020 2021 2022 SaxendaⓇ WegovyⓇ Branded AOM Market AOM: Anti-obesity medication Source: IQVIA weekly NPA, Jan 2022 Obesity care sales FY 2021 growth 57% (CER) 4.9 2021 Novo NordiskⓇ CMD22 CAPITAL MARKETS DAY

View entire presentation